文献速递泌尿生殖MRUS

持续怀疑临床显著前列腺癌患者中MRI/US融合引导活检后行MRI舱内活检的价值

MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer.
PubMed 文献 · Eur J Radiol · 2024-03-21

回顾性纳入51例mpMRI PI-RADS 4或5类、融合引导活检后未证实临床显著前列腺癌(csPC)的患者行MRI舱内活检,总体前列腺癌检出率71%、csPC检出率47%;PI-RADS 4类前列腺癌检出率58%、PI-RADS 5类94%(csPC分别为39%和61%),55%初始低级别前列腺癌患者Gleason评分升级。作者认为舱内活检可作为不确定病例的后备手段。

要点

  • PI-RADS 4或5类且融合活检阴性/不确定者,舱内活检csPC检出率47%。
  • PI-RADS 5类前列腺癌检出率94%、csPC 61%,高于4类的58%和39%。
  • csPC常位于尖部和/或前部,阅片需重点评估这些区域。

核心结论

  • 对PI-RADS 4或5类、既往融合引导活检阴性或不确定但持续怀疑csPC的患者,后续舱内活检可证实相当比例存在csPC,舱内活检可作为不确定病例的后备手段。

研究设计与样本

  • 回顾性纳入2014年1月至2022年5月间在3T mpMRI上PI-RADS 4或5类、融合引导活检后未组织学证实csPC并接受舱内活检的连续患者51例;主要目标为csPC检出率,次要目标为临床参数、MRI参数和病灶定位分析。

关键影像表现/征象

  • csPC常检出位于尖部和/或前部。
  • csPC患者前列腺体积更小、PI-RADS类别更高、前列腺特异性抗原密度(PSAD)更高且年龄更大,差异有统计学意义。

诊断标准与关键数值

  • 舱内活检总体前列腺癌检出率71%、csPC检出率47%。
  • PI-RADS 4类前列腺癌检出率58%、csPC检出率39%;PI-RADS 5类前列腺癌检出率94%、csPC检出率61%。
  • 55%初始低级别前列腺癌患者舱内活检后Gleason评分升级。

临床应用与阅片要点

  • 作者认为,对融合活检后仍持续怀疑csPC的PI-RADS 4或5类患者,舱内活检可作为不确定病例的后备手段。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Patients with suspicion of clinically significant prostate cancer (csPC) on multiparametric prostate MRI (mpMRI) but negative or inconclusive MRI/US fusion-guided biopsy (FB) can be challenging in clinical practice. To assess the utility of MRI in-bore biopsy (IB) in patients with discordant imaging and histopathological findings after FB.

METHODS: Consecutive patients with Prostate Imaging Reporting and Data System (PI-RADS) category 4 or 5 on mpMRI at 3T after FB without histologically confirmed csPC who underwent IB between 01/2014 and 05/2022, were retrospectively included. The primary objective was to assess the detection rate of csPC. Secondary objectives were to analyze clinical parameters, MRI parameters, and lesion localization.

RESULTS: In the final cohort of 51 patients, the IB resulted in an overall detection rate of 71% for PC and 47% for csPC. Furthermore, in 55% of cases with initial low-grade PC, the Gleason score was upgraded after IB. CsPC was often detected apical and/or anterior. The detection rate for PC was 58% in PI-RADS category 4 and 94% in PI-RADS category 5 (csPC 39% and 61%, respectively). Patients with csPC had statistically significant smaller prostate volumes, a higher PI-RADS category, a higher prostate-specific antigen density (PSAD), and were older.

CONCLUSIONS: For a relevant proportion of patients with PI-RADS category 4 or 5 and negative or inconclusive findings on previous FB, but with persistent suspicion of csPC, a subsequent IB verified the presence of csPC. Therefore, IB can be a backup in cases of uncertainty.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Quentin M, Boschheidgen M, Radtke JP, et al. MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer. Eur J Radiol. 2024. PMID: 38522396. doi:10.1016/j.ejrad.2024.111436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。